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Abstract
Patients who are seriously ill may ask doctors to treat them with unapproved
medication, about which not much is known, or else with known medication in a
high dosage. Apart from strict legal constraints such cases may involve difficult
ethical questions as e.g. how long a series of treatments of different patients should
be continued. Similar questions also arise in less serious situations. A physician
trusts that a certain combination of freely available drugs are efficient against
a specific disease and tries to help patients and to follow at the same time the
primum-non-nocere principle.
The objective of this paper is to contribute to the research on such questions
in the form of mathematical models. Arguing in a step-to-step approach, we will
show that certain sequential optimisation problems comply in a natural way with
the true spirit of major ethical principles in medicine. We then suggest protocols
and associate algorithms to find optimal, or approximately optimal, treatment
strategies. Although the contribution may sometimes be difficult to apply in
medical practice, the author thinks that the rational behind the approach offers
a valuable alternative for finding decision support and should attract attention.
Keywords: Expanded access, Hippocratic oath, probabilistic modelling, odds-
algorithm, unknown success probabilities, sequential estimation.
Math. subject classification: Primary 60-01, secondary 60G40.
1 Introduction
It is not evident that, apart from statistical conclusions, Mathematics may play an im-
portant role for questions of ethical behaviour in medical practice. Nevertheless, there
are situations which lead to a type of difficult ethical questions where Mathematics can
help. We speak in particular about questions which arise in compassionate use medical
treatments, also called expanded access treatments.
Patients who are seriously ill may come to see doctors, often in an act of last hope,
to treat them with unapproved medication about which not much is known, or else
previously known medication, however in a unapproved high dosage. In these cases
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one speaks of requests of a compassionate use or, synonymously, of expanded access
treatments.
1.1 Legal aspects
In most countries specific legal constraints apply for requests of compassionate use
treatments. The common denominator behind the legal constraints is the intention
to protect patients. This intention usually translates, often word by word, into the
foremost ethical principle of medicine that the expected benefit of a treatment should
outweigh the risk for a patient, or somewhat extended, outweigh the patient’s loss of
quality of life.
One cannot expect to find in different legislations a one-to-one correspondence of
sub-points of the intention to observe the ethical principle. In fact, even in societies
which are expected to be similar in their traditional and cultural background, its in-
terpretation and thus its impact on legal constraints can vary considerably. See e.g.
Darrow et al (2015), mainly concentrating on priorities in the US and relevant FDA-
regulations, and Sou (2010), summarising EU compassionate use programmes. In most
countries, a written declaration of patients is required, sometimes even with the addi-
tional requirement of being certified by a third party.
1.2 Ethical aspects
The intention that the expected benefit of a treatment of a patient should outweigh the
risk for this patient is in the same way a substantial part in the codes of medical conduct
and medical professionalism. This is evident from the ancient oath of Hippocrates (460
BC - 370 BC) over the writings of Percival (1740-1804) up to new codes such as the
Declaration of a new doctor; (see e.g. Sritharan et al. (2001).)
MacKenzie (2007) gives a clear and organised overview of the subject of medical
professionalism, dealing with several of these questions. Expanded access and compas-
sionate use programs for experimental drugs and their characterisation are also well
presented in the article by Miller et al. (2017). One notices also that compassionate
use of investigational drugs seems to attract increased interest in recent times; Bunnik
et al. (2017) relate this with a broader a change in the landscape of un-met medical
needs. We think in this paper mainly of drugs; for related questions, centered around
alternative procedures in surgery, see e.g. Angelos (2010).
If the physician agrees to a compassionate use program, then, legal aspects left
aside, ethical questions quickly take a specific meaning. How long should the treatment
with possible heavy side effects be continued? In a sequence of patients awaiting the
treatment, should the doctor decide to stop (no further treatments) if no success has
been observed so far among the patients? Similar questions for a conscientious doctor
also arise in less serious situations. For instance, the physician would like to test
the efficiency of combinations of approved treatments with known side effects. The
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primum-non-nocere principle, a pillar in ethical medical codes, implies similar questions
in a natural way, and patients would typically rely on the doctor to take the decisions.
1.3 Searching for guidelines
The conscientious doctor (he, say) may have no more than these traditional guidelines,
however. As far as compassionate use is concerned, he typically does not know enough
about the efficiency of the drug. He must try to learn from observations of treated
patients controlled with untreated patients. If there are several requests of a similar
type, he can hope to learn from sequential observation. But then, what objective
function should be optimised, and what guidelines can the doctor hope for?
These questions, shortly addressed in Bruss (2006), can be put in mathematical
models which we present below. They are kept natural and modest in the hypotheses so
that they may be used under relatively general conditions. Moreover, for these models
the answers can be found in a rather straightforward manner by the odds-algorithm
and its modifications. In principle they can always be applied, because independence is
the main requirement to apply it, and different patients react typically independently
of each other.
As far as the author is aware, neither such models nor the methodology based
on the odds-algorithm has attracted interest in the medical community. This can in
part be explained by the fact that compassionate use treatments represent fortunately
only a small percentage of medical treatments. Still, physicians confronted with such
problems may strongly appreciate advice.
The goal of the present article is to draw interest of the medical community to
this method, and this now for two more reasons. First, the odds algorithm has in
the meantime been applied in different domains, such of search strategies, investment
strategies, and robotic maintenance problems (see e.g. Ano et al. (2010), Tamaki
(2010) and Dendievel (2013) for an overview.) Second, several improvements have
been found in different directions which make both the models and the algorithms
more tractable for the real-world medical practice.
1.4 From guidelines to a first model
The idea is to develop a suitable model in a step-to-step approach.
Suppose there are ten, say, patients who ask for a compassionate use treatment.
To begin, suppose for simplicity, that these patients are all in a comparable state of
health and that the outcome of a treatment can be classified in a reasonable time span
as being a success (= clear improvement of the state of health) or else a failure (= no
improvement or deterioration.) If the doctor treated all patients sequentially he would
then see at the end a sequence of ten + or -. He cannot predict what will happen. For
learning what may happen the following Gedankenspiel may be motivating, however:
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1.5 Prophetical abilities and probabilistic reasoning
(i) The prophet. Suppose for a moment that the doctor was a prophet, able to
foresee the future of outcomes. Suppose he saw that, if he treated all ten, there would
be two, say, successes among them. Suppose moreover that as a true prophet he knows
the names of the fortunate patients. Then he treats of course only these two patients,
and informs the other eight that they should not undergo the treatment in question.
For such a prophet the situation is trivial; he has no decision problem.
(ii) The half-prophet. Let us weaken the preceding hypothesis. Our physician is
now supposed to be only a half-prophet in the sense that he would know that there
will be two successes but neither know the names of the two fortunate ones nor their
position in the queue. He could then announce the chance for success 1 in 5 to the
patients and see who would like to stay to participate under this condition. Suppose
nine of them would stay, and that after five treatments the sequence of outcomes were
−,+,−,−,+, ?6, ?7, ?8, ?9 (1)
Here the conscientious physician would stop treatments with the second success, i.e.
with the fifth patient, knowing that the following four would suffer in vain from a useless
treatment. Indeed, note that the last ”+” in such an imaginary sequence, wherever it
may be located, plays a distinguished role:
The last success in a sequence of treatments is the first one to complete the
subset of all treatments resulting in a success.
It is true that if the two success had appeared earlier the doctor could have spared
useless treatments to more patients. However, being only a half-prophet the doctor
could not know. From the ethical point of view his behaviour is irreproachable.
(iii) The physician. In reality, the doctor is neither a prophet nor a half-prophet.
However, we see here an important part of the ethical directive which follows from
the logic of the Gedankenspiel. Indeed, as long as patients stay in the sequence, the
doctor should try to sequentially maximise the probability of recognising the last + in
the sequence of treatments. The reasons are twofold, namely
(a) the last + is the first treatment covering all successful treatments in
the given sequence. Sparing treatments for the following patients increases
their quality of life and renders them free to envisage alternatives.
(b) the probability of a further + is strictly decreasing with each further
treatment.
Statement (a) is evident. (b) is not trivial, and the proof given in Bruss (2000), (see
p. 1386). Interestingly, (b) is true even if the doctor has no idea about the success
probabilities for the different patients. The essence of the proof lies in the following.
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Theorem : Suppose that there are n patients for whom the success probabilities were
known to be p1, p2, · · · , pn. Then, with qk = 1− pk, rk = pk/qk and 1 ≤ s ≤ n,
(i) The function V (n, s) defined by
V (n, s) :=
n∏
k=s
qk
n∑
j=1
rj (2)
represents the probability that the first + from patient number s onward
is the very last + in the sequence of the n patients.
(ii) The function V (n, s) is unimodal in s ∈ {1, 2, · · · , n}.
Unimodal means here that V (n, s) either decreases for all s, or else it increases up to
some smax and then decreases thereafter. If the probabilities pk and thus the odds rk
are known then (Bruss (2000)) the index s maximizing V (n, s) is determined by
s =
{
1, if
∑n
j=1 rj ≤ 1
largest k such that
∑n
j=k rj ≥ 1, otherwise.
(3)
Thus with known success probabilities, the first ethical directive for the physician is
clear. He should treat sequentially the patients up to number s−1 and then be prepared
to stop with the next successful treatment, if any, from number s onwards.
A second ethical directive may be needed in terms of a lower threshold probability
which tells when to stop if the probability of a further success becomes too small. This
lower threshold is fixed beforehand in agreement with the patients. Experience seems
to indicate that patients in compassionate use treatments are often willing to accept
particularly great risks and tend to choose this threshold quite small.
We should also mention here that prior information can sometimes be used to
improve the approach. Although patients are seen as individuals and thus independent
of each other, the doctor may want to allow for dependence within groups of patients,
for example according to sex, or according to having undergone the same history of
other treatments. Ferguson (2016) studied the use the odds-algorithm also in the
dependent case, allowing to take such situations into consideration. In the present
paper, however, our interest is confined to the case of independent reactions of patients.
2 Protocols for specific situations
In the following we shall show that organised protocols, i.e. step-to-step instructions
and recommendations can, according to different situations, help to comply with both
the patients’ priorities and ethical constraints for the physician. This method is based
on the odds algorithm (Bruss 2000) and refinements of this algorithm (Bruss (2005),
Bruss and Louchard (2009), Dendievel (2012), and Ferguson (2016). The name odds-
algorithm was coined by Bruss according to the important role played by the odds of
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events to find the optimal stopping time. The odds in the preceding Theorem 1 are
the values rk = pk/qk. The odds of an event E is simply the ratio P (E)/(1 − P (E))
where P (E) denotes the probability of an event E.
2.1 Known success probabilities
In the first protocol we suppose that both the number of patients n as well as their
respective success probabilities are known. This is in practice not very realistic but
it is the right introduction to show the essence of the method and the mathematical
simplicity of the odds-algorithm.
Protocol 1: Fixed number of patients; success probability sup-
posed to be known for each patient.
We set
n = number of patients scheduled
pk = success probability for the kth patient, k = 1, 2, · · · , n.
qk = 1− pk, k = 1, 2, · · · , n.
rk = pk/qk, k = 1, 2, · · · , n.
Algorithm for Protocol 1
Step 1: Write down in reversed order the pk, qk and rk so that the line entries qk and
rk are exactly under the line of the pk, that is
(i) pn, pn−1, pn−2, pn−3, · · ·
(ii) qn, qn−1, qn−2, qn−3, · · ·
(iii) rn, rn−1, rn−2, rn−3, · · · .
As defined above, the entries of line (ii) are 1 minus the entries of (i), and those of line
(iii) the quotients of corresponding entries in (i) and (ii).
Step 2: Form sequentially the sums rn + rn−1 + rn−2 + · · · and stop at that index
s where this sum reaches or exceeds for the first time the value 1. Otherwise, if the
consecutive sums are too small to reach 1, then put s = 1. The optimal policy is to stop
on the first success from s onwards (if any). We also obtain directly the corresponding
optimal success probability. Hence with
R(n, s) = rn + rn−1 + · · ·+ rs (4)
either R(n, s) ≥ 1 for some intermediate s, or else R(n, 1) < 1 and s = 1. Take note of
this index s and of R(n, s) and compute from line (ii) the product
Q(n, s) = qn × qn−1 × · · · × qs. (5)
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Finally, multiplying (4) and (5) yields the probability of successfully stopping on the
very last +, that is
V (n, s) = Q(n, s)R(n, s). (6)
This is all what has to be done to compute the optimal stopping index s, and V (n, s)
is the probability of an overall success, i.e. having succeeded in obtaining all possible
successes without any futile treatment thereafter. We give one numerical example.
Example: Suppose n = 7 patients with success probabilities p1 = .35, p2 = .1, p3 =
.05, p4 = .3, p5 = .1, p6 = .15, p7 = .25 queue for treatment. Then (i), (ii) and (iii) read
in reversed order (and rounded to two decimals)
.25, .15, .1, .3, .05, .1, .35
.75, .85, .9, .7, .95, .9, .65
.33, .17, .11, .43, · · · · · · · · ·
According to (3) and (4), since .33 + .17 + .11 = .61 < 1 but .33 + .17 + .11 + .43 =
1.04 > 1, we obtain s = 4. Hence the doctor should treat patients numbers 1, 2, and 3
in any case but then stop treatment after the next success, if any. The probability of
stopping with the very last success (see (6)) is thus .75× .85× .9× .7× (1.04) ≈ 0.418.
Remark One may wonder why in Step 1 the algorithm is given in terms of the
reversed order of odds. An equivalent definition of the index s in the natural order of
the r1, r2, · · · , rn is
s = smallest index k such that
n∑
j=k+1
rj < 1, 0 ≤ k ≤ n. (7)
Indeed, our first formulation in (3) has the advantage that we only have to compute
the odds as far as needed whereas, using (7), we first have to compute the sum of all
odds and then withdraw successively r1, r2, · · · until the remaining sum drops below
the value 1. However, as seen in the next protocol, the definition (7) is sometimes more
useful.
2.1.1 Influence of the order of treatments
We see from (i), (ii), (iii) and the definitions of R(n, s) and Q(n, s) in (4) and (5)
that V (n, s) may depend on the order of treatments, and in general it does. In our
example, if the physician exchanges the places of the first and the fourth patient in the
first line the values .3 and .35 are interchanged (recall the reversed order) so that now
p4 = .35, q4 = .65 and thus r4 ≈ .55 Hence V (7, 4) ≈ (.75 × .85 × .9 × .65) × (.33 +
.17 + .11 + .55) = 0.428, thus a bit larger.
There is no simple method to see the best order because V (n, s), although easy to
compute for a given order by this algorithm, is a relatively complicated discrete value
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function. Note that in theory there are 7! = 5040 possible different permutations of
treatments. However, in practice, time and other constraints on both sides, doctor and
patients, usually imply that there are only few possibilities to permute the order of
treatments. For a few possible exchanges the values V (n, s) are then easy to check.
2.1.2 Performance of the algorithm
The algorithm is optimal, that is, one cannot do better under the given hypotheses.
Moreover, with the number of operations being sub-linear in n, there exist no quicker
way to find s and V (n, s) at the same time, as proved in Bruss (2000).
We also know (Bruss (2003)) that, if the total sum of odds is at least 1 then the
optimal success probability is always above 1/e ≈ 36.78%. This may sound somewhat
disappointing, but this is just the lower bound. In fact, the effective success rate is
in practice typically more, and this for two reasons. First, if n is not large, V (n, s) is
usually above 40%. Second, and in particular, the largest part of the theoretical loss
of some 60% lies in the non-existence of successes after index s until the end. But it
suffices for the doctor to look at V (n, s+ 1), V (n, s+ 2), · · · and to stop the sequence
if these values drop below a lower threshold fixed in agreement with the patients.
Stopping may miss further successes, of course, but sparing the following patients from
the side-effects of increasingly likely useless treatments becomes an ethical priority.
We do not introduce a lower threshold in Protocol 1. This is because the success
probabilities are supposed to be known. The patients are informed and are of course
always free to leave the queue, but future events are in this model independent of
preceding observations.
A lower threshold for the probability of a further success may play an important
role, if the success probabilities are not supposed to be known, as studied in the next
Section. Protocol 1 is the simplest protocol incorporating the idea behind the odds-
algorithm. Observation-independent success probabilities are often less realistic than
unknown success probabilities.
3 Unknown success probabilities
As argued before, known success probabilities are not the typical case in compassionate
use treatments. Even if preceding parallel studies for a specific drug do exist, only
rough estimates of these can be hoped for since sample sizes are usually small. The
most difficult situation for the physician is the one where almost nothing is known
about the success probability of the drug. This is why we suppose that nothing at all
is known about success probabilities.
If n = 1 the treatment of this patient is then a deliberate trial and error, and it
makes no sense to envisage a scheme of learning. However, if n > 1, the conscientious
physician will start thinking about what statistical inference from preceding failures
and successes might possibly contribute. We need a sufficiently simple model.
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3.1 Model of compound success probability
Our way to model the unknown success probability for a given patient is to see it as
the result of two agents (as proposed, in a preliminary form, in Bruss (2006)). The
first agent is an unknown parameter p, say, where 0 < p < 1, which is interpreted as
the internal success probability of the drug. The second one is the general state of
health of the patient. For a fixed number n > 1 the physician is supposed to give the
patients 1, 2, · · · , n scores or grades for their state of health h1, h2, · · · , hn, where the
two extreme values h = 100% respectively h = 0% are seen as formal upper and lower
bound for the state of health of any person considering such a treatment.
Writing 1 for 100% and 0 for 0% we now put formally
pk := hk p, k = 1, 2, · · · , n, (8)
so that now pk is seen as the success probability of the treatment for patient number k.
Note that hk itself is not a probability but a constant chosen by the physician reducing
success probability p for patient number k. We see p as an unknown parameter and
thus put pk = hkp. If we knew p to be a random variable governed by the law L, say,
we would see pk as random variable satisfying
EL (pk) = EL (hk p) = hk EL (p) , (9)
where EL denotes the expectation with respect to the measure L. In this case we
could do better by a stepwise Bayesian inference after sequential observations, but the
knowledge of L can hardly be expected, and so we do not study this case.
There is clearly some arbitrariness for the physician in his choice of the constants
hk. However, a physician would typically be able to judge whether the state of health of
a patient compared to another is much better, or, just a bit better. If so, the physician
should not hesitate too much to choose the hk and may also rely on his feelings. It is
well known that health state interpretation can be biased by external information, as
it is, interestingly, also the case for the interpretation of findings obtained in funded
medical research (see e.g Kesselheim et al. (2012)). Actually, since p is not supposed to
be known, it may be well justified for the doctor to fix only hmin = min{hk : 1 ≤ k ≤ n}
and hmax = max{hk : 1 ≤ k ≤ n}, and to spread the remaining values equally over
[hmin, hmax] according to the perceived relative ranks of the states of health.
Now we are ready for Protocol 2. In order to facilitate the understanding of the
general idea of the new situation and of the common parts with Protocol 1, we will not
incorporate the lower threshold in this new protocol, but will do so in Protocal 3.
Protocol 2: n known, success probabilities unknown.
n = number of patients scheduled for treatment,
p = parameter thought of as being the unknown internal success probability
of the drug for a randomly chosen patient,
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hk = physician’s estimate of the state of health of patient number k with
0 < hk < 1, k = 1, 2, · · · , n,
Sk =number of successes (number of ”+”) up to the kth treatment.
We now have the formal definition
pk = hk p, qk = 1− pk, rk = pk/qk, (10)
but with the difference that the success and failure probabilities pk and qk as well as
the odds rk must be estimated sequentially, that is from the preceding observations
up to patient number k − 1. A first indication for suitable estimators comes from the
formal expectational argument, applied to (8) and (9), namely
E[Sk] = h1 p+ h2 p+ · · ·+ hk p = p(h1 + h2 + · · ·+ hk).
Hence, normalising at step k the number of successes by
∑k
j=1 hj, we have
E
[
Sk∑k
j=1 hj
]
= p (11)
so that Sk/
∑k
j=1 hj is an unbiased estimator for the unknown p at step k. It is moreover
the maximum likelihood estimator of p. Therefore we propose to use at step k
pˆk :=
Sk∑k
j=1 hj
(12)
as the estimators for p at step k = 1, 2, · · · , n− 1.
3.2 Future odds
Another impact of not knowing the success probabilities, and thus not knowing the
odds, is that the index s defined in (3) makes no longer sense. We use (7) because
the odds must now be estimated sequentially. If we replace the odds now by there
estimates at step k denoted by rˆj(k) say, we obtain correspondingly the instruction:
Stop with the kth treatment if
n∑
j=k+1
rˆj(k) < 1, 1 ≤ k ≤ n. (13)
How would we estimate at stage k these future odds rˆj for successes at stages
j = k + 1, k + 2, · · · , n− 1 given the history S1, S2, · · · , Sk? Note that, at stage k, we
do not know Sj for j > k.
We argue as follows. If p were the intrinsic success probability of the treatment
then the success probability at stage j would equal pj = phj and the corresponding
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odds would be rj = phj/(1 − phj). The last update on p given S1, S2, · · · , Sk is given
by (12) so that we propose to estimate the odds rj by
rˆj :=
hj pˆk
1− hj pˆk
. (14)
Putting Hk := h1 + h2 + · · ·+ hk, (12) becomes pˆk = Sk/Hk so that, according to (14)
the stopping index (7) translates into the rule :
Stop the sequence with the kth treatment, 1 ≤ k ≤ n, if
n∑
j=k+1
hjSk
[(Hk − hjSk)]
+
< 1, 1 ≤ k ≤ n, (15)
where [X ]+ = max{0, X}.
Forgetting for the moment the function [ · ]+, (15) becomes perfectly intuitive if we
think for a moment that all hj’s are equal. Each sum term in (15) then simplifies to
Sk/(k − Sk). This is always non-negative, since k ≥ Sk, so that [ · ]
+ can be omitted.
This is the ”empirical odds” situation at step k, that is (7) where the rj are all replaced
by the empirical odds at time k. In the more typical cases of non-identical hj’s the rˆj ’s
are health-state weighted odds.
To explain the truncation [ · ]+ note that, since the Sk’s are random variables, the
denominators of the sum terms can become negative for a relatively large hj if Sk
happens to be large. This can get in collision with the definition of odds. Thus, to
stay consistent, we impose the truncation [ · ]+ for all cases.
We also mention that the rˆj ’s are slightly biased estimators of the rj’s, but we
use them for simplicity. This seems justified since, in any case, the hj ’s bear some
subjective bias from the physician’s assessment of the health states of the patients.
3.2.1 Beginning run of failures
The condition in (14) is trivially satisfied as long as Sk = 0. This lies in the nature
of the problem. As long as there are no successes there is, from a statistical point
of view, no incentive to continue treatment. One modest way to deal with this is to
communicate to the patients still in line for treatment the current length of the run of
failures and to leave it to mutual consent on whether patients want to take the risk of
a treatment.
What would be a good alternative? Suppose that we had a well-defined inference-
based probability measure
Pˆℓ(Sn > 0) := Pˆ (Sn > 0|Sℓ = 0), ℓ ∈ {1, 2, · · · , n− 1}.
Then we could try to fix in agreement with the patients some value αℓ and rule to stop
on the first ℓ ∈ N with Pˆℓ(Sn > 0) < αℓ. However, without additional assumptions, any
choice of such a probability measure Pˆℓ seems difficult to justify. Hence, as the author
understands, for a beginning run of failures, the mutual agreement should overrule
attempts of trying to do better by a questionable quantification.
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3.3 Protocol 2: Unknown success probabilities
With the unknown odds of successes, and thus the requirement to estimate these
sequentially, an adequate algorithm will now have a different structure from the one
for Protocol 2. However, to keep it appealing to the physician, we can bring it in a
very similar form. Recall again that the rule according to inequality (15) now reads:
Stop after completion of the kth treatment, 1 ≤ k ≤ n, if
n∑
j=k+1
hjSk
Hk − hjSk
< 1, (16)
where Sk denotes the number of successes up to step k, Hk := h1 + h2 + · · · , hk and
pˆk := Sk/Hk.
3.4 Algorithm for Protocol 2
The first two lines of known constants can be written before beginning the first treat-
ment:
(i) h1 h2 h3 · · · · · ·
(ii) H1 H2 H3 · · · · · ·
When treatments begin, a third line will collect the current total number of successes
known after the kth treatment. This is the essential online ingredient of the algorithm.
(iii) S1 S2 S3 · · · · · ·
The remaining line (iv) is a deterministic function of the first three, namely
(iv) rˆ1 rˆ2 rˆ3 · · · · · ·
which are given by the successive summands in (16).
We need no separate line for the pˆj ’s and qˆj ’s in order to decide when to stop since (see
(16)). All what is needed is in the lines (i)-(iii).
3.5 Protocol 3
As mentioned before, the decision makers (doctor and patients) may convene that
the sequence should be stopped (that is, no further treatments) if a beginning run of
failures seems to become too long. For long beginning failure runs we cannot propose
a definite decision help, because the beginning Sj/Hj’s are then zero so that the pˆj ’s
are all zero.
However, as soon as there is at least a success, the pˆj’s become positive, and then
the algorithm can be used to gain additional decision help. For example, the figures
may indicate that the chances of at least one more success are still giving sufficient
motivation to continue. Therefore we propose:
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3.6 Algorithm for Protocol 3
Add to the algorithm for Protocol 2 with (i), (ii), (iii), (iv) the lines
(v) pˆ1 pˆ2 pˆ3 · · · · · ·
(vi) qˆ1 qˆ2 qˆ3 · · · · · ·
These lines can be filled in sequentially after observing S1, S2, .... Note that they can
be used to obtain the following information:
In line (v): The sum pˆk+1 + pˆk+2 + · · ·+ pˆn represents an estimate of the expected
number E(Sn − Sk) of further successes after step k.
In line (vi): The product
∏n
j=k+1 qˆj estimates the probability of P (Sn − Sk = 0),
that is, the probability of no further successes existing after step k.
Note that the preceding items of information are of interest in view of the informed
consent requirement usually seen as necessary in any expanded use program for drugs.
3.7 Optimality
In the case of unknown success probabilities no claim is made that the algorithms
yield optimality. We have proposed estimates for the pj ’s and rj’s and then applied
an online version of the odds-algorithm. Recall that the latter has been proved to be
optimal for the true pj ’s and rj’s, but finding for all n an overall optimal treatment
strategy for unknown success probabilities stays an open problem. Now, using the law
of large numbers it is easy to see that our solutions through Protocols 2 and 3 are
asymptotically optimal as n increases. This is assuring, but n is typically not very
large in practice. Nevertheless, simulations in Bruss and Louchard (2009) show that
the procedure we propose is good to very good.
Protocol 4: Unknown stream of requests.
This Protocol is a suggestion for a physician (with mathematical inclination) to es-
tablish his or her own protocol in very general situations to obtain decision help.
Often enough, neither individual success probabilities for patients nor their number
are known. Such situations occur for instance if the horizon (real time interval [0, t],
say) in which the treatments will be tested had to be fixed but where the physician
does not necessarily know how many patients will join the queue up to time t. Patients
are thought of as arriving in time according to a stochastic arrival process.
We cannot expect as much decision help as we obtained from the algorithms the
Protocols 1. to 3. since we have now much less information. As we will see below,
it is not really the randomness of the number of patients which is the problem for
proposing a good model. A more serious drawback is the unknown health scores hj
in the ”future”; the doctor cannot assess the health of unknown patients. Hence the
hj ’s must be replaced by some estimated mean mh(u) as seen at time u which weakens
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conclusions. Please note however, that this fact lies in the nature of the problem and
should therefore not be considered as a drawback in any method the physician would
propose.
We suggest here just one way to model the problem, namely, using a Poisson arrival
process:
λ(u) =rate of a (inhomogeneous) Poisson processes at time u ∈ [0, t]
Nu = number of patients arriving up to time u
Su = number of successfully treated patients until time u.
mh(u) = mean state of health score of patients seen up time u.
Pu (Nu,Su) = predicted internal success probability for the treatment of a patient
arriving in ]u, t], knowing the history of arrivals and successes up to time u.
The arrival rate or intensity λ(u) should be estimated according to the doctor’s
experience. If no additional information is available, the doctor may see any arrival
time as equally likely and model λ(u) as being a constant function over the horizon
[0, t]. For instance, if he thinks that he may expect a total of roughly r requests
(arrivals) in [0, t], then he may use λ(u) := r/t.
The estimates used for Pu can the be obtained similarly to our approach in Protocol
2 if we interpret the arrival times of patients as the times when the evaluations of the
treatments in success or failure are available. However, in a specific situation the
physician may be well in a position to use estimates based on more information.
Suggested strategy for Protocol 4:
Refuse new treatment requests from the first time s onwards with
ˆ t
s
λ(u)Ps (Nu,Su)mh(s) du ≤ 1. (17)
Justification of the suggested strategy:
To understand this suggestion we refer to section 4.1 on page 1389 of Bruss (2000)
combined with Lemma 5.1 on page 3252 of Bruss and Yor (2012).
Actually, it is not crucial that the arrival processes is a Poisson process. What is
essential is that this arrival process is a process with independent increments, and the
Poisson process has this property. But we propose to use a Poisson process because
then the mentioned references Bruss(2000) and Bruss and Yor (2012) directly explain
our suggested strategy. Moreover, a Poisson process is particularly convenient model.
With independent increments it is of course understood that the intensity λ(u) of
the Poisson arrival process does not depend on previous successes and failures. Unless
[0, t] is large, in the order of two years or more, this assumption can be well defended.
According to a few simulations, the quality of such a strategy as suggested in
Protocol 4 seems good if the expected number of arrivals is not too small. In practice
the stream of arrivals in compassionate use programmes can be very small, and the
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author regrets not to be able to make a better suggestion for such a case. For more
standard treatments with approved drugs and known side effects, this seems much less
important, of course.
Having said this, there are two sides to the coin. Thinking specifically about the
context of compassionate use, whether being the physician or a possible patient, it is
equally comforting to see cases where only very few patients have to face such serious
treatments.
Conclusion
Stopping a sequence of treatments with the very last success is, from a medical ethical
point of view, an objective which stands out. Stopping on the last success realises all
possible successes and minimises the number of future futile treatments. A conscien-
tious physician without prophetical capacities cannot but translate this objective into
the objective of maximising the probability of stopping with the very last success. This
paper proposes Protocols to find the optimal or close to optimal solution in an easily
computable and organised way. These protocols also allow for lower safety thresholds
to control for the risk, due to randomness, of continuing too long in waiting for im-
probable further successes. Finally, the article also discusses in Protocol 4 a suggestion
to deal with the difficult case of an unknown stream of requests for treatments.
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